Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

but one of the conclusions of the pilot was that a pre-requisite for adoption will be "robust systems in place ensuring that the patient can easily access the package leaflet for their medicine in ...

LAHORE: The Punjab government announced on Friday that those seeking assistance under the Nighaban Ramazan package should get themselves registered by Feb 15. It also announced that registration ...

DAVOS, Switzerland, Jan 24 (Reuters) - Saudi Economy Minister Faisal Alibrahim said on Friday that the kingdom's $600 billion expanded package with the United States includes investments as well ...

This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults, ...

1 ONAPGO. Package insert. Supernus Pharmaceuticals, Inc. *Efficacy results from the analysis of data from the TOLEDO study using the FDA’s preferred methodology, mixed-effects model for repeated ...

This repository contains the manifest files for the Windows Package Manager default source. You are highly encouraged to submit manifests for your favorite application. This project welcomes ...